Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine [Phase 1, Phase 2]
Phase 1/2 trial update of alisertib (MLN8237) in relapsed or refractory aggressive B-cell lymphomas treated with rituximab with or without v…
-
CLINICAL_TRIALS trial_result · 2018-03-19Clinical Trial Update: Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas [Phase 2]
Phase 2 clinical trial update on peptide receptor radionuclide therapy with yttrium-90 DOTATOC in relapsed/refractory diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2018-03-12Clinical Trial Update: Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. [Phase 1, Phase 2]
This completed Phase 1/2 study evaluated a combination of lenalidomide, bendamustine, and rituximab as first-line therapy in patients over 6…
-
CLINICAL_TRIALS trial_result · 2018-03-09Clinical Trial Update: Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL [Phase 2]
Phase 2 study evaluating bendamustine, lenalidomide, and rituximab as second-line therapy for first-relapsed/refractory mantle cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2018-03-06Clinical Trial Update: Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating vorinostat in multiple low-grade non-Hodgkin lymphomas, including MALT lymphoma, nodal marginal zone lymphoma, foll…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-02-09Clinical Trial Update: Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients [Phase 3]
A Phase III randomized trial comparing lenalidomide versus observation after induction with rituximab followed by chemotherapy and autologou…
-
CLINICAL_TRIALS trial_result · 2017-12-19Clinical Trial Update: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma [Phase 3]
Phase 3 clinical trial evaluating autologous stem cell transplant after a rituximab/ibrutinib/arac-containing induction in generalized mantl…
-
CLINICAL_TRIALS trial_result · 2017-11-28Clinical Trial Update: Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD [Phase 2]
Phase 2 trial evaluating rituximab as prophylaxis to prevent chronic graft-versus-host disease after allogeneic stem cell transplantation; t…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma [Phase 2]
This Phase 2 trial evaluated the combination of vorinostat, cladribine, and rituximab in patients with mantle cell lymphoma, relapsed chroni…
-
CLINICAL_TRIALS trial_result · 2017-10-30Clinical Trial Update: Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL [Phase 2]
Phase 2 study of the R-GemOx regimen (rituximab, gemcitabine, and oxaliplatin) evaluating efficacy and tolerance in diffuse large B-cell lym…
-
CLINICAL_TRIALS trial_result · 2017-10-20Clinical Trial Update: Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating Bevacizumab combined with CHOP and Rituximab as first-line therapy for untreated mantle cell lymphoma; results were…
-
CLINICAL_TRIALS trial_result · 2017-10-19Clinical Trial Update: A Safety Study of SGN-CD19A for B-Cell Lymphoma [Phase 1]
Phase 1 safety study of SGN-CD19A in various B-cell lymphomas has completed; the update summarizes safety results across multiple indication…
-
CLINICAL_TRIALS trial_result · 2017-09-12Clinical Trial Update: Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma [Phase 2]
A Phase II clinical trial evaluating the RT-PEPC regimen in relapsed mantle cell lymphoma has completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-09-11Clinical Trial Update: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating temsirolimus with bendamustine and rituximab in relapsed follicular lymphoma or mantle cell lymphoma has been com…
-
CLINICAL_TRIALS trial_result · 2017-08-07Clinical Trial Update: Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) [Phase 1]
A Phase 1 trial update discusses the combination of bortezomib, cladribine, and rituximab (VCR) for Mantle Cell Lymphoma.
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies [Phase 2]
A Phase 2 trial evaluating a combination of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with previously treated lymph…
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial investigating rituximab with combination chemotherapy or bendamustine followed by consolidation and stem cell transplantation …
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a combination of vorinostat, rituximab, ifosfamide, carboplatin, and etoposide in adults with relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a multi-modality approach combining Yttrium-90 ibritumomab tiuxetan, fludarabine, radiation therapy, and d…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS trial_result · 2017-05-19Clinical Trial Update: Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma [Phase 4]
A Phase 4 trial comparing two doses of temsirolimus (Torisel) in patients with mantle cell lymphoma/non-Hodgkin's lymphoma has completed wit…
-
CLINICAL_TRIALS trial_result · 2017-05-17Clinical Trial Update: Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer [Phase 2]
Phase 2 trial evaluating haploidentical donor bone marrow transplantation in patients with high-risk hematologic cancers; results completed …
-
CLINICAL_TRIALS trial_result · 2017-05-12Clinical Trial Update: Safety and Tolerability of HSC835 in Patients With Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and tolerability of HSC835 in patients with various hematologic malignancies completed with results posted …
-
CLINICAL_TRIALS trial_result · 2017-05-10Clinical Trial Update: Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating bortezomib plus vorinostat as maintenance after autologous stem cell transplant in non-Hodgkin lymphoma showed resu…
-
CLINICAL_TRIALS trial_result · 2017-05-08Clinical Trial Update: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of oral clofarabine in relapsed/refractory non-Hodgkin lymphoma completed with posted results.